WallStSmart

Fonar Corporation (FONR)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 42160% more annual revenue ($44.56B vs $105.43M). TMO leads profitability with a 15.0% profit margin vs 7.1%. FONR trades at a lower P/E of 13.3x. TMO earns a higher WallStSmart Score of 59/100 (C).

FONR

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 4.5Value: 5.7Quality: 5.0

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FONRSignificantly Overvalued (-146.1%)

Margin of Safety

-146.1%

Fair Value

$7.55

Current Price

$18.59

$11.04 premium

UndervaluedFair: $7.55Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.29

$105.47 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FONR2 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

P/E RatioValuation
13.3x8/10

Attractively priced relative to earnings

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

FONR4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Market CapQuality
$92.74M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.8%3/10

ROE of 5.8% — below average capital efficiency

Profit MarginProfitability
7.1%3/10

7.1% margin — thin

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FONR

The strongest argument for FONR centers on Price/Book, P/E Ratio.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : FONR

The primary concerns for FONR are Revenue Growth, Market Cap, Return on Equity.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

FONR carries more volatility with a beta of 0.99 — expect wider price swings.

TMO is growing revenue faster at 7.2% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TMO scores higher overall (59/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fonar Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

FONAR Corporation is engaged in the research, development, production, and marketing of Magnetic Resonance Imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company is headquartered in Melville, New York.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?